文献速递治疗药物监测与药物基因组学抗栓抗凝管理特殊人群用药

东亚与欧洲人群药物基因组学差异的群体基因组学解析

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans.
PubMed 文献 · Clin Pharmacol Ther · 2026-06-03

该研究利用公共基因组数据集系统评估东亚与欧洲人群的药物基因组学变异差异,发现东亚人群药物反应降低相关变异频率总体较低,药物相关基因群体分化程度约为全基因组背景的三倍,并揭示SLCO1B3/SLCO1B7等转运基因及VKORC1、SH2B3等位点的群体差异与选择信号。

要点

  • 药物相关基因群体分化程度约为全基因组背景的三倍(FST=0.18 vs. 0.06)。
  • SLCO1B3/SLCO1B7累积等位基因概率东亚18.69% vs. 欧洲91.60%。
  • VKORC1-rs9923231-T在东亚人群显示选择信号(XP-EHH=3.58)。

核心结论

  • 东亚与欧洲人群在药物基因组学变异分布上存在群体水平差异,药物相关基因分化程度高于全基因组背景。
  • 东亚人群药物反应降低相关药物基因组学变异频率总体低于欧洲人群。
  • 将群体多样性纳入药物基因组学研究并制定群体特异性药物反应指南对全球精准医学具有重要意义。

研究设计与样本

  • 利用公共基因组数据集系统评估东亚人群与欧洲人群的药物基因组学变异。
  • 采用群体遗传学分析探究塑造药物基因组学差异的潜在演化动力。

主要发现

  • 药物相关基因群体分化程度为全基因组背景的三倍(FST=0.18 vs. 0.06)。
  • SLCO1B3/SLCO1B7累积等位基因概率东亚为18.69%、欧洲为91.60%。
  • 东亚人群药物基因组学变异显示更强的正选择信号,可能反映对病原体和饮食压力的历史适应。
  • VKORC1-rs9923231-T等位基因增强华法林敏感性,在东亚人群显示选择证据(XP-EHH=3.58),可能与维生素K摄入相关。
  • 欧洲人群富集的SH2B3-rs3184504-T等位基因频率为欧洲0.46 vs. 东亚0.003,与血压调节相关选择有关。

临床怎么用

  • 临床用药及药物基因组学解读应考虑东亚与欧洲人群间药物基因组学变异频率的群体差异。
  • 华法林等药物相关基因(如VKORC1)的群体差异提示剂量或敏感性评估需结合人群背景。
  • SLCO1B3/SLCO1B7等转运基因的群体分化提示药物转运与药代动力学可能存在群体差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential evolutionary forces shaping these differences. Our analyses revealed that EAS populations generally harbor a lower frequency of pharmacogenomic variants previously associated with reduced drug response compared with EUR populations, indicating population-level differences in the distribution of PGx variants. Drug-associated genes exhibited threefold higher population differentiation than the genome-wide background (FST = 0.18 vs. 0.06). Key transport genes such as SLCO1B3/SLCO1B7 showed striking differences in cumulative allele probability (EAS: 18.69% vs. EUR: 91.60%), suggesting population-level divergence in drug transport and pharmacokinetics. Population genetic analyses revealed stronger signals of positive selection on PGx variants in EAS populations, likely reflecting historical adaptations to pathogen and dietary pressures. For instance, the VKORC1-rs9923231-T allele, which enhances warfarin sensitivity, shows evidence of selection in EAS populations (XP-EHH = 3.58) and may relate to vitamin K intake. Conversely, the EUR-enriched SH2B3-rs3184504-T allele (AFEUR: 0.46 vs. AFEAS: 0.003) has been associated with selection related to blood pressure regulation. Collectively, these findings highlight the importance of incorporating population diversity into pharmacogenomic research and underscore the potential need for population-specific drug response guidelines to advance global precision medicine.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chen S, Chen H, Xu S, et al. Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans. Clin Pharmacol Ther. 2026. PMID: 42233542. doi:10.1002/cpt.70354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。